Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · May 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to use MRI scans to classify how well rectal cancer is responding to treatment. The researchers want to create a method called mrTRG (MRI-based tumor response regression) that can help predict how a patient's cancer will progress after they receive neoadjuvant therapy, which is treatment given before surgery. By comparing the results from MRI scans to the results from standard pathology tests, they hope to improve how doctors assess treatment responses in rectal cancer patients.

To be eligible for this trial, participants must have a confirmed diagnosis of primary rectal cancer that is locally advanced and be scheduled to receive neoadjuvant therapy followed by surgery. Patients should expect to undergo MRI scans before and after their treatment and will also have regular follow-ups after their surgery. It’s important to note that individuals with a history of other cancers, those who undergo surgery without prior treatment, or those who cannot complete their treatment will not qualify for this study. Overall, this trial aims to enhance how we monitor and understand treatment effectiveness in rectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • biopsy-proved primary rectal cancer
• • baseline MRI confirmed LARC (cT3 and/or cN+)
• • scheduled to take neoadjuvant therapy
• • receive baseline and preoperative pelvic MRI
• • receive TME surgery after NAT
• • have routine follow-up after the operation
• Exclusion Criteria:
• • history of malignancy or multiple primary cancers
• • receive surgery directly without NAT
• • don't receive TME surgery
• • don't complete NAT
• • simultaneous distant metastasis at the baseline diagnosis
• • lack of baseline or preoperative pelvic MRI
• • incomplete or unavailable pathological information
• • lost to follow-up within three months after surgery (lost since the first follow-up visit)